Skip to main content

Table 4 Phase II studies of gemcitabine/paclitaxel in patients with advanced or metastatic breast cancer

From: First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

Author Regimen No. of Pts ORR % (CR %) Median TTP (mos) Comments
Vici et al26 G 1500 mg/m2 d1, 15 + T150 mg/m2 d1, 15 q4wks 20 45% (10%) 8 Heavily pretreated pts; supported with G-CSF
Colomer et al27 G 2500 mg/m2 d1 + T150 mg/m2 d1 q2wks 43 68% (21%) 9 Previously treated pts; hematologic toxicity
Delfino et al28 G 1200 mg/m2 d1, 8 + T 175 mg/m2 d1 q3wks 45 67% (22%) 11 Chemonaïve pts; mild hematologic toxicity; manageable toxicity
Sanchez-Rovira et al29 G 2500 mg/m2 d1, 15 + T 135 mg/m2 d1, 15 q4wks 44 45% (7%) 7 Previously treated pts; hematologic and neurologic toxicities
Murad et al30 G 1000 mg/m2 d1, 8 + T 175 mg/m2 d1 q3wks 29 55% (17%) 8 Heavily pretreated pts; 28-day reduced to a 21-day schedule due to hematologic toxicity
Genot et al (current study) G 1200 mg/m2 d1, 8 T 175 mg/m2 d1 q3wks 40 40% (5.7%) 7.2 No prior treatment for metastatic disease, neutropenia prominent, other toxicities mild
  1. ORR = overall response rate; CR = complete response; TTP = time to progression; mos = months; G = gemcitabine; T = paclitaxel.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us